The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Protein kinase A inhibitor proteins (PKIs) divert GPCR‐Gαs‐cAMP signaling toward EPAC and ERK activation and are involved in tumor growth
Abstract
The PKA‐inhibitor (PKI) family members PKIα, PKIβ, and PKIγ bind with high affinity to PKA and block its kinase activity, modulating the extent, and duration of PKA‐mediated signaling events. While PKA is a well‐known regulator of physiological and oncogenic events, the role of PKI proteins in these pathways has remained elusive. Here, by measuring activation of the MAPK pathway downstream of GPCR‐Gαs‐cAMP signaling, we show that the expression levels of PKI proteins can alter the balance of activation of two major cAMP targets: PKA and EPAC. Our results indicate that PKA maintains repressive control over MAPK signaling as well as a negative feedback on cAMP concentration. Overexpression of PKI and its subsequent repression of PKA dysregulates these signaling pathways, resulting in increased intracellular cAMP, and enhanced activation of EPAC and MAPK. We also find that amplifications of PKIA are common in prostate cancer and are associated with reduced progression free survival. Depletion of PKIA in prostate cancer cells leads to reduced migration, increased sensitivity to anoikis and reduced tumor growth. By altering PKA activity PKI can act as a molecular switch, driving GPCR‐Gαs‐cAMP signaling toward activation of EPAC‐RAP1 and MAPK, ultimately modulating tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, PKI is now linked to several cancers.”
From Edmond Fischer's kinase legacy: History of the protein kinase inhibitor and protein kinase A (2023) · cites this paper as [32]
In the citing paper
“More recently the expression of PKI was shown to be elevated in many cancer cells”
From Edmond Fischer's kinase legacy: History of the protein kinase inhibitor and protein kinase A (2023) · cites this paper as [32]
In the citing paper
“using activation of MAPK as a downstream readout of PKA signaling and tumor growth, expression of IP20 led to a reduction in tumor growth 32.”
From Edmond Fischer's kinase legacy: History of the protein kinase inhibitor and protein kinase A (2023) · cites this paper as [32]
In the citing paper
“Inhibition of PKA by the IP20 peptide showed enhanced survival and increased MAPK activation.”
From Edmond Fischer's kinase legacy: History of the protein kinase inhibitor and protein kinase A (2023) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
Self-citationVerbruggen, F., Aron, A. R., Band, G. P., Beste, C., Bissett, P. G., Brockett, A. T., Brown, J. W., Chamberlain, S. R., Chambers, C. D., Colonius, H., et al. (2019) · eLife · doi:10.7554/elife.46323 · Cited by 990
Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability
Pattabiraman, D. R., Bierie, B., Kober, K. I., Thiru, P., Krall, J. A., Zill, C., Reinhardt, F., Tam, W. L., & Weinberg, R. A. (2016) · Science · doi:10.1126/science.aad3680 · Cited by 332
Iglesias-Bartolome, R., Patel, V., Cotrim, A., Leelahavanichkul, K., Molinolo, A. A., Mitchell, J. B., & Gutkind, J. S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.06.007 · Cited by 284
Research works printed but not linked: 61
- 10.1038/nrc3521 · DOI · Paper page
- 10.1056/NEJM199112123252403 · DOI · Paper page
- 10.1038/340692a0 · DOI · Paper page
- 10.1038/ncb3164 · DOI · Paper page
- 10.1038/nm.3666 · DOI
- 10.1016/j.ccr.2014.02.004 · DOI · Paper page
- 10.1111/j.1745-7270.2008.00438.x · DOI · Paper page
- 10.1016/S0962-8924(02)02294-8 · DOI · Paper page
- 10.1002/jcp.21246 · DOI · Paper page
- 10.1038/sj.onc.1210407 · DOI · Paper page
- 10.1124/pr.110.003707 · DOI · Paper page
- Jewell JL, 2019, GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor, eLife, 8, 1, 10.7554/eLife.43038 · DOI
- 10.1038/emboj.2013.102 · DOI · Paper page
- 10.1101/gad.219402.113 · DOI · Paper page
- Ashby CD, 1972, Characterization of the interaction of a protein inhibitor with adenosine 3',5'‐monophosphate‐dependent protein kinases. I. Interaction with the catalytic subunit of the protein kinase, J Biol Chem, 247, 6637, 10.1016/S0021-9258(19)44739-X · DOI · Paper page
- Ashby CD, 1973, Characterization of the interaction of a protein inhibitor with adenosine 3′,5′‐monophosphate‐dependent protein kinases. II. Mechanism of action with the holoenzyme, J Biol Chem, 248, 1255, 10.1016/S0021-9258(19)44290-7 · DOI · Paper page
- 10.1016/j.npep.2005.10.002 · DOI · Paper page
- 10.1146/annurev.bi.59.070190.004543 · DOI · Paper page
- 10.1016/S0021-9258(18)31623-5 · DOI
- 10.1016/0092-8674(95)90435-2 · DOI · Paper page
- 10.1128/MCB.20.10.3442-3448.2000 · DOI · Paper page
- 10.1128/MCB.21.12.3959-3963.2001 · DOI · Paper page
- 10.1161/CIRCRESAHA.112.273896 · DOI
- 10.1074/jbc.M113.466904 · DOI
- 10.1016/j.molcel.2012.10.018 · DOI · Paper page
- 10.1126/scitranslmed.aap8798 · DOI · Paper page
- 10.1158/2159-8290.CD-12-0095 · DOI · Paper page
- 10.1126/scisignal.2004088 · DOI · Paper page
- 10.1038/24884 · DOI · Paper page
- 10.1146/annurev.pharmtox.010909.105714 · DOI · Paper page
- Bos JL, 2018, From Ras to Rap and back, a journey of 35 years, Cold Spring Harb Perspect Med, 8, 1
- 10.1074/jbc.273.23.14533 · DOI
- 10.1074/jbc.M403604200 · DOI
- 10.1128/MCB.26.6.2130-2145.2006 · DOI · Paper page
- 10.1101/lm.830008 · DOI
- 10.1073/pnas.1210209109 · DOI
- 10.1038/srep09344 · DOI
- 10.1016/S0092-8674(00)80184-1 · DOI · Paper page
- 10.1074/jbc.M003327200 · DOI
- 10.1177/1947601911407323 · DOI · Paper page
- 10.1074/jbc.M116.768986 · DOI
- 10.1093/emboj/16.21.6426 · DOI · Paper page
- 10.1002/jcp.21354 · DOI
- 10.1128/MCB.22.17.6023-6033.2002 · DOI · Paper page
- 10.1073/pnas.0813263106 · DOI
- 10.1074/jbc.M201491200 · DOI
- 10.1074/jbc.270.21.12481 · DOI · Paper page
- 10.1016/j.molcel.2006.07.025 · DOI · Paper page
- 10.1161/01.RES.0000256354.95791.f1 · DOI · Paper page
- 10.1007/978-1-61779-160-4_14 · doi:10.1007/978-1-61779-160-4_14
- 10.1021/cb8000414 · DOI · Paper page
- 10.1038/nrc2809 · DOI · Paper page
- 10.2174/1875397301004010084 · DOI · Paper page
- 10.1242/jcs.072165 · DOI · Paper page
- 10.1074/jbc.C300182200 · DOI · Paper page
- 10.1016/j.celrep.2015.01.046 · DOI · Paper page
- 10.1038/s41418-020-0522-3 · DOI · Paper page
- 10.1002/(SICI)1097-4547(19980801)53:3<269::AID-JNR1>3.0.CO;2-8 · DOI · Paper page
- 10.1038/onc.2009.144 · DOI · Paper page
- Manschwetus JT, 2019, A Stapled peptide mimic of the pseudosubstrate inhibitor PKI inhibits protein kinase A, Molecules, 24, 1, 10.3390/molecules24081567 · DOI · Paper page
- 10.1016/j.celrep.2016.02.077 · DOI
Cited by
Edmond Fischer's kinase legacy: History of the protein kinase inhibitor and protein kinase A
Taylor, S. S., Herberg, F. W., Veglia, G., & Wu, J. (2023) · IUBMB Life · doi:10.1002/iub.2714 · Cited by 15
Metadata
- Authors
- Hoy, J. J., Salinas Parra, N., Park, J., Kuhn, S., & Iglesias‐Bartolome, R.
- Affiliations
- Laboratory of Cellular and Molecular Biology Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda MD USA
- Collaborative Bioinformatics Resource Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda MD USA
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2020-08-24
- Volume
- 34
- Issue
- 10
- Pages
- 13900-13917
- ISSN
- 0892-6638
- 1530-6860
- Cited by
- 46
- References
- 4
- Language
- en
- Funders
- National Cancer Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protein kinase A inhibitor proteins (PKIs) divert GPCR‐Gαs‐cAMP signaling toward EPAC and ERK activation and are involved in tumor growth. https://app.cochat.ai/papers/10.1096/fj.202001515r
- The paper
- Hoy, J. J., Salinas Parra, N., Park, J., Kuhn, S., & Iglesias‐Bartolome, R. (2020). Protein kinase A inhibitor proteins (PKIs) divert GPCR‐Gαs‐cAMP signaling toward EPAC and ERK activation and are involved in tumor growth. The FASEB Journal. https://doi.org/10.1096/fj.202001515r
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.